Form D · Biotechnology
ProteoWise Inc.
New Haven, CT · CIK 0001807738
Offering snapshot reported Dec 13, 2024 · SEC filing
- Reported sold
- $2.31M Offering amount: $10M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 6, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 13, 2024 | Initial | $2,306,020 | No comparison | 6 | SEC filing |
| Apr 13, 2021 | Initial | $2,653,558 | No comparison | 5 | SEC filing |
| Mar 27, 2020 | Initial | $6,295,940 | No comparison | 15 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-532014
Source: Form D, filed Dec 13, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Benjamin D. Comb | Director |
| Erik Gunther | Director, Executive |
| David Smoller | Director |
| Daniel Wagner | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
85 Willow Street
New Haven, CT, 06511
New Haven, CT, 06511